Theriva Biologics, Inc. (TOVX)

US — Healthcare Sector
Peers: LUMO  DFFN  AVTX  CBIO  PBLA  VRPX  REVB  BDRX  PRAX  FWBI  SLRX  SABS  VCNX  GOVX  KTRA  FRTX  LSTA  MRKR  XCUR  PTIX  PMVP 

Automate Your Wheel Strategy on TOVX

With Tiblio's Option Bot, you can configure your own wheel strategy including TOVX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol TOVX
  • Rev/Share 0.0553
  • Book/Share 5.5696
  • PB 0.0846
  • Debt/Equity 0.0872
  • CurrentRatio 1.5312
  • ROIC -1.03

 

  • MktCap 3856072.0
  • FreeCF/Share -6.0425
  • PFCF -0.2294
  • PE -0.0528
  • Debt/Assets 0.042
  • DivYield 0
  • ROE -1.1429

 

  • Rating B
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 5
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Theriva Biologics, Inc. (TOVX)

  • IPO Date 2006-12-18
  • Website https://therivabio.com
  • Industry Biotechnology
  • CEO Mr. Steven A. Shallcross CPA
  • Employees 20
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.